Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: High Dose Vitamin C Clear all
Terminated Phase 1 Interventional Results available

High Dose Vitamin C in Cardiac Surgery Patients

NCT02762331
View directory record Official record
Conditions
Disorder of Vitamin C, Atrial Fibrillation, Complications Due to Coronary Artery Bypass Graft, Heart Valve Disease
Interventions
Ascorbic Acid, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 12, 2026, 5:30 PM EDT
Completed No phase listed Observational

Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

NCT03276481
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Oral microbiota assessment, Comprehensive chemical gustometry, Measurement of salivary flow, Surveys assessing taste disturbances
Diagnostic Test · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 12, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients

NCT00974025
View directory record Official record
Conditions
Fontan Procedure, Hypoplastic Left Heart Syndrome, Tricuspid Atresia
Interventions
Vitamin C, Placebo
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
8 Years to 25 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 12, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

NCT00469209
View directory record Official record
Conditions
Myeloma
Interventions
Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 12, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

Study of High-Dose Intravenous (IV) Vitamin C Treatment in Patients With Solid Tumors

NCT00441207
View directory record Official record
Conditions
Cancer
Interventions
Ascorbic Acid
Drug
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 12, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

NCT01852890
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Ascorbate, Gemcitabine, Radiation therapy
Drug · Radiation
Lead sponsor
Joseph J. Cullen
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 12, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma

NCT01891747
View directory record Official record
Conditions
Malignant Glioma
Interventions
Bevacizumab, Temozolomide, Vitamin C
Drug · Dietary Supplement
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 12, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer

NCT01049880
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Gemcitabine with escalating ascorbic acid
Drug
Lead sponsor
Joseph J. Cullen
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 12, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Evaluation of Jarro-Dophilus EPS® Probiotic Formulations

NCT02693314
View directory record Official record
Conditions
Healthy
Interventions
Jarro-Dophilus EPS® (5 billion CFU/capsule), Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule), Placebo
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 12, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

NCT03410030
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreas Metastases
Interventions
High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2, Gemcitabine 1000mg/m^2, High Dose Ascorbic Acid 37.5 g/m^2, High Dose Ascorbic Acid 56.25 g/m^2, High Dose Ascorbic Acid 75 g/m^2
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 12, 2026, 5:30 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

NCT03066115
View directory record Official record
Conditions
Hypoxia, Hypercapnia
Interventions
L-NMMA, Ketorolac, Ascorbic Acid, Intravenous Catheter, Transcranial Doppler Ultrasound
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 12, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

High Dose Ascorbic Acid for Plasma Cell Disorders

NCT03602235
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ascorbate, Melphalan
Other · Drug
Lead sponsor
Christopher Strouse
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 12, 2026, 5:30 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

NCT02905591
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions
Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 12, 2026, 5:30 PM EDT
Withdrawn Phase 2 Interventional

Vitamin C for Severe Thermal Injuries

NCT01587261
View directory record Official record
Conditions
Severe Thermal Injury, Greater Than 20% TBSA
Interventions
Vitamin C, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 12, 2026, 5:30 PM EDT
Recruiting Phase 1 Interventional

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

NCT07177079
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax, High-dose ascorbate, Decitabine
Drug
Lead sponsor
Kittika Poonsombudlert
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 12, 2026, 5:30 PM EDT
Withdrawn Phase 2 Interventional

A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients

NCT03541486
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
Ascorbate, Gemcitabine, radiation therapy
Drug · Radiation
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 12, 2026, 5:30 PM EDT
Recruiting Phase 2 Interventional

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
High Dose SAB-142, Low Dose SAB-142, Placebo
Drug · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
5 Years to 40 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
23
States / cities
San Francisco, California • San Jose, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 12, 2026, 5:30 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 12, 2026, 5:30 PM EDT
Withdrawn Phase 4 Interventional

Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty

NCT02926651
View directory record Official record
Conditions
Anemia, Arthritis, Total Knee Arthroplasty, Total Hip Arthroplasty
Interventions
Conventional Oral TXA (Tranexamic Acid), Multi-Dose Oral TXA (Tranexamic Acid)
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 12, 2026, 5:30 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

The Effect of Nutritional Supplementation on Actinic Purpura: A Pilot Study

NCT06840574
View directory record Official record
Conditions
Skin Health, Skin Aging of Face and Hands, Healthy, Ecchymosis
Interventions
Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, Low Dose Vitamin C, High Dose Vitamin C
Dietary Supplement
Lead sponsor
Standard Process Inc.
Industry
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 12, 2026, 5:30 PM EDT
Withdrawn Phase 1Phase 2 Interventional

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

NCT03797443
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Ascorbic Acid, nab paclitaxel, Cisplatin, Gemcitabine
Drug
Lead sponsor
Piedmont Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Fayetteville, Georgia • Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 12, 2026, 5:30 PM EDT
Recruiting Early Phase 1 Interventional

Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

NCT03849443
View directory record Official record
Conditions
Open Posterior Thoracolumbar Spinal Fusion Procedure
Interventions
Tranexamic Acid Injectable Product (1000 mg intravenous bolus), Vitamin C 250 MG Oral Tablet, Tranexamic Acid 650Mg Tablet
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 12, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ascorbic Acid (Vitamin C) Infusion in Human Sepsis

NCT01434121
View directory record Official record
Conditions
Sepsis, Septic Shock, Hypotension, Acute Lung Injury
Interventions
Ascorbic Acid, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 12, 2026, 5:30 PM EDT
Active, not recruiting Phase 1 Interventional Results available

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

NCT04900792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide
Drug · Radiation
Lead sponsor
Bryan Allen
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 12, 2026, 5:30 PM EDT